Talk:Ancillary testing in prostate cancer

MSI testing - in BRCA1/2: Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O (August 2020). "Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA". J Immunother Cancer 8 (2). doi:10.1136/jitc-2020-001065. PMC 7422632. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422632/.